DRESS syndrome

Last Updated: 2026-11-19

Author(s): Anzengruber F., Navarini A.

ICD11: EH65

Publication History

Version 1

29 January 2021

Version 2

19 November 2026

Hypersensitivity syndrome, DRESS, drug reaction with eosinophilia and systemic symptoms, drug reaction with eosinophilia and systemic symptoms syndrome, aromatic amine anticonvulsant hypersensitivity syndrome

Drug-induced hypersensitivity syndrome.

Independent of sex and age. Familial clustering is possible.

Drugs:

  • Anticonvulsants (including non-aromatic agents such as levetiracetam)

    • Carbamazepine

    • Phenytoin

    • Phenobarbital

  • Sulfonamides

  • Allopurinol

  • Gold salts

  • Dapsone

  • Sorbinil

  • Strontium ranelate

  • Minocycline; vancomycin; beta-lactam antibiotics

Drug-specific HLA susceptibility, immune activation and herpesvirus reactivation contribute; no single enzyme defect explains DRESS.

  • Onset is usually 2–8 weeks after starting a culprit drug, but may be earlier with antibiotics or re-exposure.

  • Maculopapular, lichenoid, morbilliform exanthem, sometimes progressing to erythroderma.

  • Fever

  • Hepatopathy

  • Interstitial nephropathy

  • Pulmonary involvement

  • Cardiac involvement (myocarditis, pericardium)

  • Haematological changes (eosinophilia, agranulocytosis, pancytopenia, appearance of atypical lymphocytes)

  • Splenomegaly

  • Lymph node enlargement

  • Facial oedema is a common clue; eosinophilia or organ injury may appear after the initial rash, so early normal tests do not exclude evolving disease.

The original RegiSCAR inclusion checklist and the weighted diagnostic validation score serve different purposes. The first table maps the checklist features to their scoring contribution; use the complete validation-score table below to calculate the total.

Use the validated RegiSCAR scoring system: <2 excludes DRESS; 2–3 suggests possible DRESS; 4–5 indicates probable DRESS; and ≥6 indicates definite DRESS. Exclude competing causes.

Clinical feature in the inclusion checklist

Contribution to the RegiSCAR validation score

Hospitalisation

No independent points

Reaction suspected to be drug-related

No independent points

Acute rash

No points for its presence alone; extent and morphology are scored below

Fever ≥38.5°C*

Present: 0; absent or unknown: −1

Enlarged lymph nodes at a minimum of 2 sites*

+1 if nodes are >1 cm at ≥2 sites; otherwise 0

Involvement of at least 1 internal organ*

One organ: +1; ≥2 organs: +2 maximum; absent / unknown: 0

Blood count abnormalities*

No additional aggregate points; use the specific findings below

Lymphocytes above or below normal limits

No points for the count alone; atypical lymphocytes score +1

Eosinophils above the laboratory limits

+1 or +2 only at the thresholds in the scoring table below

Platelets below the laboratory limits

No independent points

* Inclusion-checklist legend: At least three of the four starred features were required, in addition to hospitalisation, suspected drug causation and an acute rash. Blood count abnormalities form one category. This historical inclusion checklist is distinct from the weighted validation score. Choudhary et al., 2013, Table 3.

RegiSCAR validation score

Criterion

Points

Fever ≥38.5°C

Yes: 0; no / unknown: −1

Lymph nodes >1 cm at ≥2 sites

Yes: +1; no / unknown: 0

Eosinophilia

700–1499/µL: +1; ≥1500/µL: +2; below threshold / unknown: 0

Eosinophilia when leukocytes <4000/µL

Use percentages instead: 10–19.9%: +1; ≥20%: +2; <10% / unknown: 0

Atypical lymphocytes

Present: +1; absent / unknown: 0

Rash covering >50% of body surface area

Yes: +1; no / unknown: 0

Rash suggesting DRESS†

Yes: +1; no: −1; unknown: 0

Skin biopsy suggesting DRESS

Compatible / unknown / not performed: 0; suggesting another diagnosis: −1

Internal organ involvement‡

One organ: +1; ≥2 organs: +2 maximum; none / unknown: 0

Resolution taking ≥15 days

Yes: 0; no / unknown: −1

Alternative causes investigated§

Qualifying negative work-up: +1; otherwise: 0

† At least two of: facial oedema, infiltration, purpura outside the legs, or psoriasiform desquamation.

‡ Count only organ involvement not explained by another cause: liver, kidney, lung, muscle / heart, pancreas or another organ. The combined organ score is capped at +2.

§ At least three negative investigations, with none positive, from ANA, blood culture, hepatitis A / B / C serology, and Chlamydia / Mycoplasma testing.

Use either the absolute eosinophil count or, in leukopenia, the percentage; do not add both. Sum the validation-score table only. Total: −4 to +9; <2: no case; 2–3: possible; 4–5: probable; ≥6: definite. Reassess evolving cases as additional findings become available.

Sources: Kardaun et al., prospective RegiSCAR study, 2013; RegiSCAR validation-score table; Spanish DRESS guideline, Table 8.

DRESS is an emergency.

  • Record all medicines and onset dates, assess organ involvement and apply the validated RegiSCAR score.

  • Check differential blood count, liver tests, bilirubin / INR, creatinine and urinalysis serially.

  • Investigate cardiac or respiratory symptoms urgently; myocarditis may be delayed.

  • Biopsy can exclude mimics but is not diagnostic.

  • Do not re-expose to confirm causality.

  • Hepatopathy

  • Interstitial nephropathy

  • Pulmonary involvement

  • Cardiac involvement (myocarditis, pericardium)

  • Haematological changes (eosinophilia, agranulocytosis, pancytopenia, appearance of atypical lymphocytes)

  • Splenomegaly

  • Lymph node enlargement

Severity varies and prognosis cannot be predicted with certainty; severe organ complications can be fatal. Long-term follow-up is required even after resolution, as autoimmune diseases such as thyroiditis or type 1 diabetes may develop months to years later. Document the culprit drug in writing and inform patients of the risk of recurrence with re-exposure.

Withdraw culprit / suspect drugs immediately. Mild disease may need potent topical corticosteroids and close monitoring; consider systemic corticosteroids for moderate disease and use them for severe organ injury with multidisciplinary care. Taper over weeks to months according to recovery. Skin severity does not predict internal injury. Investigate herpesvirus reactivation where available; reserve antivirals for significant viral disease. Refractory disease needs specialist advice; IVIG alone is not standard treatment. Monitor organ recovery and delayed autoimmune sequelae.

In children, involve paediatric allergy / dermatology early. The 2025 EAACI paper recommends admission for suspected DRESS, severity-based treatment and close follow-up; adult steroid regimens should not be extrapolated automatically. A RegiSCAR score of 2–3 may represent ambiguous / evolving disease requiring monitoring rather than reassurance.

When rescue immunomodulation is considered, distinguish the evidence-based DRESS regimen from the medicine’s licensed indications. Ciclosporin, IVIG or biologic rescue for DRESS is specialist-directed off-label treatment in the cited European guidance; select the actual preparation and monitoring plan rather than borrowing a regimen approved for another disease.

  1. Descamps V, Ranger-Rogez S. DRESS syndrome. Joint Bone Spine. 2014 Jan;81(1):15-21.

  2. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol. 2013 May;68(5):693.e1-14.

  3. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol. 2013 May;68(5):709.e1-9; quiz 718-20.

  4. López-Rocha E, Blancas L, Rodríguez-Mireles K, Gaspar-López A, O'Farrill-Romanillos P, Amaya-Mejía A, Galindo-Pacheco L, Campos-Romero F, Aguilar-Hinojosa N, Suárez G. Prevalence of DRESS syndrome. Rev Alerg Mex. 2014 Jan-Mar;61(1):14-23.

  5. Sonal Choudhary, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. J Clin Aesthet Dermatol. 2013 Jun;6(6): 31–37.

  6. DRESS syndrome: an interaction between drugs, latent viruses, and the immune system☆. Available online.

  7. Brüggen, et al. Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus. JAMA Dermatol. 2024;160:37–44. doi:10.1001/jamadermatol.2023.4450.

  8. South African National Department of Health. Primary Healthcare skin conditions update: DRESS and levetiracetam, June 2026. Available online.

  9. Kuyucu S, Blanca-Lopez N, Caubet JC, et al. Clinical diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) in children: An EAACI position paper. Pediatr Allergy Immunol. 2025;36(7):e70103. doi:10.1111/pai.70103.